Navigation Links
Scientists discover the basis of allergic reactions

Allergies in humans and animals are on the increase. An allergic reaction may cause unpleasant symptoms like hay fever, food intolerance or skin rashes. Allergic reactions may also cause acute and life-threatening symptoms, such as asthma or anaphylactic shock.

A single pollen protein is responsible for allergies

One of the most well known allergens, i.e. substances that cause allergies, is so-called "Bet v 1" from birch pollen (Betula verrucosa). The protein was first produced artificially in the laboratory 25 years ago in Vienna, and is being used as an allergen model for research throughout the world. "Bet v 1" is the principal allergen among hundreds of other proteins of birch pollen. It renders the immune system hypersensitive and leads to the formation of disease-causing antibodies known as IgE immunoglobulins in 95 percent of persons with a pollen allergy.

Birch pollen protein in its iron-loaded state is not allergenic

Until recently it was not known why harmless molecules trigger allergies at all. Scientist Franziska Roth-Walter and her colleagues from the Messerli Research Institute have now found the possible cause. The birch pollen protein "Bet v 1" is very similar to the human protein Lipocalin 2 in terms of structure; Lipocalin 2 is mainly present in the lung. Lipocalin 2 and "Bet v 1" possess so-called molecular pockets with which they can bind iron. When these pockets remain empty, the birch pollen protein becomes an allergen and is liable to cause allergic reactions in humans and animals. The protein manipulates so-called T-helper 2 cells (Th2 cells), a certain type of immune cells, towards allergy. The human protein Lipocalin 2 also performs tasks of the immune system, depending on its iron loading.

Origin of allergy investigated in the model of birch pollen

In allergic people and other mammals, Th2 cells are predominant compared to Th1 cells. Th2 cells play an important role in allergic reactions and in combating parasites. Th1 cells serve to defend the body against bacterial and viral infections. "A typical feature of allergies is the disruption of the balance between the Th1 and Th2 immune response," explains Professor Erika Jensen-Jarolim, head of the Department of Comparative Medicine at the Messerli Research Institute.

"Investigations currently in progress indicate that we can directly transfer the principle of birch pollen allergens to other allergens with a similar molecular structure. We are thus starting to understand - for the first time - why allergies to pollen, foodstuffs and fungal spores actually arise in the first place."

Environmental factors determine the iron loading of the pollen protein

Scientists at the Messerli Research Institute, a combined facility of the Vetmeduni Vienna, the Meduni Vienna an der University of Vienna, are currently investigating the mechanisms that may contribute to reduced iron loading of "Bet v 1" in plants. "Iron loading of the birch protein may be connected to the aggravated environmental conditions acting on plants," says Jensen-Jarolim. "In fact, there may be a direct connection between environmental pollution and rising allergy statistics. The most important conclusion from our work is that, in the future, it would make sense to specifically load allergenic molecules of the "Bet v 1" type with iron when they are used as allergy-specific immunotherapy in allergic patients. By doing so, this treatment - which currently takes two to four years - can be greatly shortened and its efficiency can thus be enhanced."


Contact: Erika Jensen-Jarolim
University of Veterinary Medicine -- Vienna

Related biology news :

1. MU scientists successfully transplant, grow stem cells in pigs
2. Scientists capture most detailed images yet of humans tiny cellular machines
3. NUS scientists demonstrate rare chemical phenomenon to harvest solar energy
4. Glow-in-the-dark tool lets scientists find diseased bats
5. Listening helps scientists track bats without exposing the animals to disease
6. Scientists control rapid re-wiring of brain circuits using patterned visual stimulation
7. Vines choke a forests ability to capture carbon, Smithsonian scientists report
8. Imaging scientists develop a better tool for tracking MS
9. Scientists map the worst times of day for people allergic to grass pollen
10. Scientists discover potential new target for cancer immunotherapy
11. Two Norwegian neuroscientists receive the 2014 Körber European Science Prize
Post Your Comments:
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: